Martin Štefanič

Rhenium 188–labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

Donald Bunjes, Inga Buchmann, Christian Duncker et al. · Blood · 2001 · 168 citations · Full text

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

K. Mross, Martin Štefanič, Daniela Gmehling et al. · Clinical Cancer Research · 2009 · 164 citations

Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant.

Bernd Hertenstein, Martin Štefanič, T Schmeiser et al. · Journal of Clinical Oncology · 1994 · 154 citations

Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia

W. Digel, Martin Štefanič, W Schöniger et al. · Blood · 1989 · 149 citations · Full text

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

Martin Reck, R. Kaiser, C. Eschbach et al. · Annals of Oncology · 2011 · 149 citations · Full text

Medicine, Clinical Trials, Bronchial Neoplasm +6